Annual CFF
$67.44 M
+$72.56 M+1415.63%
31 December 2023
Summary:
ANI Pharmaceuticals annual cash flow from financing activities is currently $67.44 million, with the most recent change of +$72.56 million (+1415.63%) on 31 December 2023. During the last 3 years, it has risen by +$68.88 million (+4786.52%). ANIP annual CFF is now -65.34% below its all-time high of $194.59 million, reached on 31 December 2021.ANIP Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$291.03 M
+$292.48 M+20143.39%
30 September 2024
Summary:
ANI Pharmaceuticals quarterly cash flow from financing activities is currently $291.03 million, with the most recent change of +$292.48 million (+20143.39%) on 30 September 2024. Over the past year, it has increased by +$287.27 million (+7650.47%). ANIP quarterly CFF is now at all-time high.ANIP Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$257.93 M
+$287.27 M+979.09%
30 September 2024
Summary:
ANI Pharmaceuticals TTM cash flow from financing activities is currently $257.93 million, with the most recent change of +$287.27 million (+979.09%) on 30 September 2024. Over the past year, it has increased by +$179.09 million (+227.12%). ANIP TTM CFF is now at all-time high.ANIP TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ANIP Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1415.6% | +7650.5% | +227.1% |
| 3 y3 years | +4786.5% | +9730.4% | +1892.8% |
| 5 y5 years | +342.4% | +10000.0% | +1094.7% |
ANIP Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -65.3% | +1415.6% | at high | +1575.4% | at high | +979.1% |
| 5 y | 5 years | -65.3% | +342.4% | at high | +1575.4% | at high | +979.1% |
| alltime | all time | -65.3% | +342.4% | at high | +1141.4% | at high | +979.1% |
ANI Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $291.03 M(<-9900.0%) | $257.93 M(-979.1%) |
| June 2024 | - | -$1.45 M(-92.6%) | -$29.34 M(-156.1%) |
| Mar 2024 | - | -$19.73 M(+65.5%) | $52.26 M(-22.5%) |
| Dec 2023 | $67.44 M(-1415.6%) | -$11.92 M(-417.4%) | $67.44 M(-14.5%) |
| Sept 2023 | - | $3.75 M(-95.3%) | $78.85 M(+6.3%) |
| June 2023 | - | $80.15 M(-1862.3%) | $74.18 M(-1101.9%) |
| Mar 2023 | - | -$4.55 M(+795.3%) | -$7.40 M(+44.4%) |
| Dec 2022 | -$5.13 M(-102.6%) | -$508.00 K(-44.2%) | -$5.13 M(-102.9%) |
| Sept 2022 | - | -$911.00 K(-36.6%) | $174.83 M(+1.2%) |
| June 2022 | - | -$1.44 M(-36.7%) | $172.72 M(-11.5%) |
| Mar 2022 | - | -$2.27 M(-101.3%) | $195.05 M(+0.2%) |
| Dec 2021 | $194.59 M(<-9900.0%) | $179.44 M(-6037.9%) | $194.59 M(+1403.5%) |
| Sept 2021 | - | -$3.02 M(-114.5%) | $12.94 M(-4.7%) |
| June 2021 | - | $20.90 M(-866.9%) | $13.59 M(-175.3%) |
| Mar 2021 | - | -$2.73 M(+23.4%) | -$18.05 M(+1154.7%) |
| Dec 2020 | -$1.44 M(-215.1%) | -$2.21 M(-7.1%) | -$1.44 M(<-9900.0%) |
| Sept 2020 | - | -$2.38 M(-77.9%) | $3000.00(-99.8%) |
| June 2020 | - | -$10.74 M(-177.3%) | $1.61 M(-88.4%) |
| Mar 2020 | - | $13.89 M(-1913.4%) | $13.94 M(+1014.8%) |
| Dec 2019 | $1.25 M(-104.5%) | -$766.00 K(-0.5%) | $1.25 M(-104.8%) |
| Sept 2019 | - | -$770.00 K(-148.7%) | -$25.93 M(+0.2%) |
| June 2019 | - | $1.58 M(+31.0%) | -$25.89 M(-3.3%) |
| Mar 2019 | - | $1.21 M(-104.3%) | -$26.78 M(-3.7%) |
| Dec 2018 | -$27.82 M(-138.4%) | -$27.95 M(+3723.0%) | -$27.82 M(-158.5%) |
| Sept 2018 | - | -$731.00 K(-205.8%) | $47.55 M(+9.7%) |
| June 2018 | - | $691.00 K(+306.5%) | $43.35 M(+2.0%) |
| Mar 2018 | - | $170.00 K(-99.6%) | $42.50 M(-41.3%) |
| Dec 2017 | $72.36 M(<-9900.0%) | $47.42 M(-1060.0%) | $72.36 M(+184.3%) |
| Sept 2017 | - | -$4.94 M(+3128.8%) | $25.45 M(-19.3%) |
| June 2017 | - | -$153.00 K(-100.5%) | $31.54 M(-0.4%) |
| Mar 2017 | - | $30.02 M(+5696.3%) | $31.65 M(-4441.7%) |
| Dec 2016 | -$729.00 K(-168.4%) | $518.00 K(-54.8%) | -$729.00 K(-32.1%) |
| Sept 2016 | - | $1.15 M(-3115.8%) | -$1.07 M(-28.7%) |
| June 2016 | - | -$38.00 K(-98.4%) | -$1.50 M(+15.1%) |
| Mar 2016 | - | -$2.35 M(-1453.4%) | -$1.31 M(-222.6%) |
| Dec 2015 | $1.07 M(-99.4%) | $174.00 K(-75.6%) | $1.07 M(-99.1%) |
| Sept 2015 | - | $714.00 K(+346.3%) | $124.48 M(+0.2%) |
| June 2015 | - | $160.00 K(+788.9%) | $124.22 M(+0.2%) |
| Mar 2015 | - | $18.00 K(-100.0%) | $123.95 M(-27.8%) |
| Dec 2014 | $171.65 M(-4753.1%) | $123.58 M(>+9900.0%) | $171.65 M(+251.2%) |
| Sept 2014 | - | $458.00 K(-505.3%) | $48.88 M(+0.9%) |
| June 2014 | - | -$113.00 K(-100.2%) | $48.42 M(+10.0%) |
| Mar 2014 | - | $47.72 M(+5799.1%) | $44.03 M(-1293.7%) |
| Dec 2013 | -$3.69 M(-206.3%) | $809.00 K(>+9900.0%) | -$3.69 M(-18.1%) |
| Sept 2013 | - | $0.00(-100.0%) | -$4.51 M(+339.2%) |
| June 2013 | - | -$4.50 M(>+9900.0%) | -$1.03 M(-129.6%) |
| Dec 2012 | $3.47 M(-94.9%) | -$7900.00(-100.2%) | $3.47 M(+65.0%) |
| Sept 2012 | - | $3.48 M(<-9900.0%) | $2.10 M(-95.2%) |
| June 2012 | - | -$700.00(-99.9%) | $43.78 M(-35.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | $67.66 M(+39.6%) | -$1.38 M(-103.0%) | $67.66 M(-21.2%) |
| Sept 2011 | - | $45.16 M(<-9900.0%) | $85.90 M(+110.8%) |
| June 2011 | - | -$13.30 K(-100.1%) | $40.74 M(-25.8%) |
| Mar 2011 | - | $23.89 M(+41.6%) | $54.87 M(+13.2%) |
| Dec 2010 | $48.45 M(+43.9%) | $16.87 M(<-9900.0%) | $48.45 M(-11.0%) |
| Sept 2010 | - | -$300.00(-100.0%) | $54.43 M(-16.7%) |
| June 2010 | - | $14.12 M(-19.2%) | $65.34 M(+27.7%) |
| Mar 2010 | - | $17.47 M(-23.5%) | $51.15 M(+51.9%) |
| Dec 2009 | $33.67 M(>+9900.0%) | $22.84 M(+109.3%) | $33.67 M(+212.6%) |
| Sept 2009 | - | $10.91 M(<-9900.0%) | $10.77 M(+5205.1%) |
| June 2009 | - | -$70.00 K(+460.0%) | $203.00 K(-33.9%) |
| Mar 2009 | - | -$12.50 K(-79.3%) | $307.00 K(-3.9%) |
| Dec 2008 | $319.40 K(-98.3%) | -$60.30 K(-117.4%) | $319.50 K(-21.0%) |
| Sept 2008 | - | $345.80 K(+917.1%) | $404.50 K(+100.8%) |
| June 2008 | - | $34.00 K(>+9900.0%) | $201.40 K(-98.9%) |
| Mar 2008 | - | $0.00(-100.0%) | $18.35 M(-0.8%) |
| Dec 2007 | $18.49 M(+150.5%) | $24.70 K(-82.7%) | $18.49 M(+0.1%) |
| Sept 2007 | - | $142.70 K(-99.2%) | $18.47 M(-27.5%) |
| June 2007 | - | $18.18 M(>+9900.0%) | $25.47 M(+249.8%) |
| Mar 2007 | - | $142.70 K(>+9900.0%) | $7.28 M(-1.4%) |
| Dec 2006 | $7.38 M(+3633.2%) | $0.00(-100.0%) | $7.38 M(0.0%) |
| Sept 2006 | - | $7.15 M(<-9900.0%) | $7.38 M(+3010.5%) |
| June 2006 | - | -$6300.00(-102.6%) | $237.40 K(-16.5%) |
| Mar 2006 | - | $243.70 K(>+9900.0%) | $284.30 K(+43.7%) |
| Dec 2005 | $197.80 K(-98.9%) | $0.00(0.0%) | $197.80 K(-53.3%) |
| Sept 2005 | - | $0.00(-100.0%) | $423.90 K(-44.7%) |
| June 2005 | - | $40.60 K(-74.2%) | $766.30 K(-95.7%) |
| Mar 2005 | - | $157.20 K(-30.5%) | $17.85 M(-4.5%) |
| Dec 2004 | $18.68 M(+91.0%) | $226.10 K(-34.0%) | $18.68 M(+0.5%) |
| Sept 2004 | - | $342.40 K(-98.0%) | $18.58 M(-33.4%) |
| June 2004 | - | $17.12 M(+1626.5%) | $27.90 M(+158.9%) |
| Mar 2004 | - | $991.60 K(+695.8%) | $10.77 M(+10.1%) |
| Dec 2003 | $9.78 M(+123.2%) | $124.60 K(-98.7%) | $9.78 M(+1.8%) |
| Sept 2003 | - | $9.66 M(<-9900.0%) | $9.60 M(+117.0%) |
| June 2003 | - | -$2800.00(<-9900.0%) | $4.43 M(+1.0%) |
| Mar 2003 | - | $0.00(-100.0%) | $4.38 M(+0.0%) |
| Dec 2002 | $4.38 M(+15.3%) | -$53.00 K(-101.2%) | $4.38 M(+0.9%) |
| Sept 2002 | - | $4.48 M(<-9900.0%) | $4.34 M(+5350.2%) |
| June 2002 | - | -$45.50 K(+3400.0%) | $79.70 K(-80.2%) |
| Mar 2002 | - | -$1300.00(-98.6%) | $401.80 K(-89.4%) |
| Dec 2001 | $3.80 M(+617.2%) | -$91.90 K(-142.1%) | $3.80 M(-0.9%) |
| Sept 2001 | - | $218.40 K(-21.0%) | $3.83 M(-8.3%) |
| June 2001 | - | $276.60 K(-91.9%) | $4.18 M(+6.7%) |
| Mar 2001 | - | $3.40 M(-5958.6%) | $3.92 M(+639.0%) |
| Dec 2000 | $530.00 K(-87.5%) | -$58.00 K(-110.3%) | $530.10 K(-9.9%) |
| Sept 2000 | - | $565.10 K(+4420.8%) | $588.10 K(+2457.0%) |
| June 2000 | - | $12.50 K(+19.0%) | $23.00 K(+119.0%) |
| Mar 2000 | - | $10.50 K | $10.50 K |
| Dec 1999 | $4.23 M(-0.8%) | - | - |
| Dec 1998 | $4.26 M | - | - |
FAQ
- What is ANI Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for ANI Pharmaceuticals?
- What is ANI Pharmaceuticals annual CFF year-on-year change?
- What is ANI Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for ANI Pharmaceuticals?
- What is ANI Pharmaceuticals quarterly CFF year-on-year change?
- What is ANI Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for ANI Pharmaceuticals?
- What is ANI Pharmaceuticals TTM CFF year-on-year change?
What is ANI Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of ANIP is $67.44 M
What is the all time high annual CFF for ANI Pharmaceuticals?
ANI Pharmaceuticals all-time high annual cash flow from financing activities is $194.59 M
What is ANI Pharmaceuticals annual CFF year-on-year change?
Over the past year, ANIP annual cash flow from financing activities has changed by +$72.56 M (+1415.63%)
What is ANI Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of ANIP is $291.03 M
What is the all time high quarterly CFF for ANI Pharmaceuticals?
ANI Pharmaceuticals all-time high quarterly cash flow from financing activities is $291.03 M
What is ANI Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, ANIP quarterly cash flow from financing activities has changed by +$287.27 M (+7650.47%)
What is ANI Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of ANIP is $257.93 M
What is the all time high TTM CFF for ANI Pharmaceuticals?
ANI Pharmaceuticals all-time high TTM cash flow from financing activities is $257.93 M
What is ANI Pharmaceuticals TTM CFF year-on-year change?
Over the past year, ANIP TTM cash flow from financing activities has changed by +$179.09 M (+227.12%)